Guggenheim analyst Dana Flanders assumed coverage of Teva Pharmaceuticals with a Neutral rating and a $6-$8 fair value range, saying that "expectations for global generics appear right sized." Flanders believes the company should be able to meaningfully address its debt over the next 3-5 years, but noted it will also have to contend with opioid litigation and price collusion litigation that cost $4B-$8B and $1B, respectively. He added that Teva will need to address both its branded pipeline and biosimilars in the medium-term future.

Vanda Pharmaceuticals "announced that the Supreme Court denied Vanda's petition for a writ of certiorari in its HETLIOZ(R) Abbreviated New Drug Application litigation against Teva Pharmaceuticals USA, Inc., Apotex Inc. and Apotex Corp." CEO Mihael H. Polymeropoulos stated: "We are disappointed that the Supreme Court has decided not to hear our case and clarify the lower court standard for obviousness in patent law. However, we are pleased that our case has drawn attention to an area of law that has broad and significant implications in life sciences innovation."